Reports Of Intussusception Prompt Label Change For Merck’s RotaTeq
This article was originally published in The Pink Sheet Daily
Executive Summary
Postmarketing surveillance identified 28 cases of intussusception from the approximately 3.5 million doses distributed.
You may also be interested in...
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.
GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.
GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease
Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.